Staying at the forefront of innovative cellular reprogramming technologies, ReproCELL’s Stemgent RNA Reprogramming portfolio is being expanded to include a cellular reprogramming kit using self-replicative RNA (srRNA) to reprogram both human blood outgrowth endothelial progenitor cells (EPCs) and human fibroblasts to generate clinically relevant iPS cells. The srRNA reprogramming of EPCs into iPS cells is the first demonstrated commercial application of RNA for the cellular reprogramming of a blood-derived cell type. The non-viral/non-DNA nature of RNA reprogramming leads to clinically relevant iPS cell lines that are suitable for GMP-compliant research studies.